Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P. Offidani M, et al. Among authors: leoni p. Blood. 2006 Oct 1;108(7):2159-64. doi: 10.1182/blood-2006-03-013086. Epub 2006 Jun 8. Blood. 2006. PMID: 16763209 Free article. Clinical Trial.
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P. Olivieri A, et al. Among authors: leoni p. Biol Blood Marrow Transplant. 2005 Aug;11(8):627-36. doi: 10.1016/j.bbmt.2005.05.002. Biol Blood Marrow Transplant. 2005. PMID: 16041313 Free article.
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P. Offidani M, et al. Among authors: leoni p. Haematologica. 2006 Jan;91(1):133-6. Haematologica. 2006. PMID: 16434383 Clinical Trial.
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Tassetti A, Scortechini AR, Offidani M, Mulattieri S, Stronati A, Brandozzi G, Giacchetti A, Mozzicafreddo G, Ricotti G, Filosa G, Bettacchi A, Simonacci M, Novelli N, Leoni P. Pulini S, et al. Among authors: leoni p. Haematologica. 2007 May;92(5):686-9. doi: 10.3324/haematol.10879. Haematologica. 2007. PMID: 17488695 Free article. Clinical Trial.
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: leoni p. Clin Lymphoma Myeloma. 2008 Oct;8(5):294-9. doi: 10.3816/CLM.2008.n.041. Clin Lymphoma Myeloma. 2008. PMID: 18854284
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Gentili S, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Samori A, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: leoni p. Br J Haematol. 2009 Mar;144(5):653-9. doi: 10.1111/j.1365-2141.2008.07495.x. Epub 2008 Nov 13. Br J Haematol. 2009. PMID: 19036082 Free article. Clinical Trial.
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Savini A, Alesiani F, Brunori M, Catarini M, Visani G, Samori A, Burattini M, Centurioni R, Montanari M, Fraticelli P, Ruggieri M, Falcioni S, Galieni P. Offidani M, et al. Among authors: leoni p. Eur J Haematol. 2010 Jun;84(6):474-83. doi: 10.1111/j.1600-0609.2010.01418.x. Epub 2010 Mar 11. Eur J Haematol. 2010. PMID: 20331733 Clinical Trial.
308 results